Choose Your Country or Region

Anti-Stat3α Rabbit Antibody [F6J12]

Catalog No.: F0511

Application: Reactivity: Human, Mouse, Rat, Hamster, Monkey

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:500 IF1:200 CHIP1:100

Application
WB, IP, IHC, IF, ChIP

Reactivity
Human, Mouse, Rat, Hamster, Monkey

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
86 kDa

Positive Control	Human colon carcinoma; Raji cell; ACHN cell; BaF3 cell; COS-7 cell; H-4-II-E cell; HeLa cell; Hep G2 cell
Negative Control	PC-3 cell

Datasheet & SDS

Biological Description

Specificity
Anti-Stat3α Rabbit Antibody [F6J12] detects endogenous levels of total Stat3α protein.

Clone
F6J12

Synonym(s)
Signal transducer and activator of transcription 3, Acute-phase response factor, APRF, STAT3

Background
STAT3α is the full-length, canonical isoform of Signal Transducer and Activator of Transcription 3 (STAT3), a latent cytoplasmic transcription factor that mediates signaling downstream of cytokines, growth factors, and hormones, most notably interleukin-6 (IL-6). Structurally, STAT3α contains six functional domains: an N-terminal domain for cooperative DNA binding, a coiled-coil domain mediating protein–protein interactions, a central DNA-binding domain, a linker domain, an SH2 domain required for receptor docking and dimerization, and a C-terminal transactivation domain (TAD) that harbors critical phosphorylation sites at Tyr705 and Ser727. Upon cytokine or growth factor stimulation, JAK kinases phosphorylate Tyr705, promoting STAT3α dimerization via SH2–phosphotyrosine interactions, nuclear translocation, and direct binding to GAS elements in target gene promoters. STAT3α is ubiquitously expressed across tissues and is essential for embryonic and perinatal development, regulating genes involved in survival, proliferation, differentiation, angiogenesis, and immune responses. While tightly controlled under physiological conditions, constitutive activation of STAT3α is frequently observed in cancers, where it functions as an oncogenic driver by upregulating anti-apoptotic proteins (e.g., Bcl-xL, survivin), cell cycle regulators (e.g., cyclin D1), and pro-angiogenic factors (e.g., VEGF), thereby supporting tumor initiation, progression, metastasis, and therapy resistance.

Background

STAT3α is the full-length, canonical isoform of Signal Transducer and Activator of Transcription 3 (STAT3), a latent cytoplasmic transcription factor that mediates signaling downstream of cytokines, growth factors, and hormones, most notably interleukin-6 (IL-6). Structurally, STAT3α contains six functional domains: an N-terminal domain for cooperative DNA binding, a coiled-coil domain mediating protein–protein interactions, a central DNA-binding domain, a linker domain, an SH2 domain required for receptor docking and dimerization, and a C-terminal transactivation domain (TAD) that harbors critical phosphorylation sites at Tyr705 and Ser727. Upon cytokine or growth factor stimulation, JAK kinases phosphorylate Tyr705, promoting STAT3α dimerization via SH2–phosphotyrosine interactions, nuclear translocation, and direct binding to GAS elements in target gene promoters. STAT3α is ubiquitously expressed across tissues and is essential for embryonic and perinatal development, regulating genes involved in survival, proliferation, differentiation, angiogenesis, and immune responses. While tightly controlled under physiological conditions, constitutive activation of STAT3α is frequently observed in cancers, where it functions as an oncogenic driver by upregulating anti-apoptotic proteins (e.g., Bcl-xL, survivin), cell cycle regulators (e.g., cyclin D1), and pro-angiogenic factors (e.g., VEGF), thereby supporting tumor initiation, progression, metastasis, and therapy resistance.

References
https://pubmed.ncbi.nlm.nih.gov/30031681/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%